Insider Transactions in Q1 2021 at Cvs Health Corp (CVS)
Insider Transaction List (Q1 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 31
2021
|
James David Clark SVP, Cont & Chief Acct Officer |
SELL
Open market or private sale
|
Direct |
5,350
-42.48%
|
$406,600
$76.0 P/Share
|
|
Mar 31
2021
|
James David Clark SVP, Cont & Chief Acct Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,350
+29.82%
|
$395,900
$74.29 P/Share
|
|
Mar 29
2021
|
Thomas M Moriarty EVP & General Counsel |
SELL
Open market or private sale
|
Direct |
62,943
-100.0%
|
$4,783,668
$76.15 P/Share
|
|
Mar 29
2021
|
Thomas M Moriarty EVP & General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
62,943
+50.0%
|
$4,657,782
$74.29 P/Share
|
|
Mar 26
2021
|
Larry J Merlo Director |
SELL
Open market or private sale
|
Direct |
270,650
-34.06%
|
$20,028,100
$74.73 P/Share
|
|
Mar 26
2021
|
Larry J Merlo Director |
BUY
Exercise of conversion of derivative security
|
Direct |
271,347
+25.45%
|
$20,079,678
$74.29 P/Share
|
|
Mar 26
2021
|
Jonathan C Roberts EVP & Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
73,433
-99.11%
|
$5,434,042
$74.49 P/Share
|
|
Mar 26
2021
|
Jonathan C Roberts EVP & Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
73,433
+49.78%
|
$5,434,042
$74.29 P/Share
|
|
Mar 19
2021
|
Thomas M Moriarty EVP & General Counsel |
SELL
Open market or private sale
|
Indirect |
49,211
-72.97%
|
$3,641,614
$74.15 P/Share
|
|
Mar 16
2021
|
Eva C Boratto EVP & CFO |
SELL
Open market or private sale
|
Direct |
18,882
-20.99%
|
$1,397,268
$74.68 P/Share
|
|
Mar 16
2021
|
Eva C Boratto EVP & CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
18,882
+17.35%
|
$1,397,268
$74.29 P/Share
|
|
Mar 02
2021
|
Daniel P Finke EVP/Pres, Health Care Benefits |
SELL
Payment of exercise price or tax liability
|
Direct |
2,413
-13.8%
|
$164,084
$68.94 P/Share
|
|
Feb 28
2021
|
James David Clark SVP, Cont & Chief Acct Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,129
-13.48%
|
$76,772
$68.13 P/Share
|
|
Feb 28
2021
|
Joshua Matthew Flum EVP, ENT STRATEGY & DIGITAL |
SELL
Payment of exercise price or tax liability
|
Direct |
572
-2.18%
|
-
|
|
Feb 26
2021
|
Laurie P. Havanec EVP and Chief People Officer |
BUY
Grant, award, or other acquisition
|
Direct |
44,033
+50.0%
|
$2,994,244
$68.13 P/Share
|
|
Feb 17
2021
|
Edward J Ludwig Director |
BUY
Open market or private purchase
|
Direct |
3,000
+17.31%
|
$216,000
$72.0 P/Share
|
|
Feb 01
2021
|
Lisa Bisaccia Former EVP & Chief HR Officer |
BUY
Grant, award, or other acquisition
|
Direct |
77,457
+43.62%
|
-
|
|
Feb 01
2021
|
Troyen A Brennan EVP and Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
94,516
+32.64%
|
-
|
|
Feb 01
2021
|
Eva C Boratto EVP & CFO |
BUY
Grant, award, or other acquisition
|
Direct |
88,500
+35.67%
|
-
|
|
Feb 01
2021
|
James David Clark SVP, Cont & Chief Acct Officer |
BUY
Grant, award, or other acquisition
|
Direct |
13,113
+42.24%
|
-
|
|
Feb 01
2021
|
Daniel P Finke EVP/Pres, Health Care Benefits |
BUY
Grant, award, or other acquisition
|
Direct |
14,280
+37.23%
|
-
|
|
Feb 01
2021
|
Alan Lotvin EVP&President-PharmacyServices |
BUY
Grant, award, or other acquisition
|
Direct |
95,669
+47.88%
|
-
|
|
Feb 01
2021
|
Karen S Lynch President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
95,302
+50.0%
|
-
|
|
Feb 01
2021
|
Larry J Merlo Director |
BUY
Grant, award, or other acquisition
|
Direct |
180,192
+20.39%
|
-
|
|
Feb 01
2021
|
Thomas M Moriarty EVP & General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
124,048
+50.0%
|
-
|
|
Feb 01
2021
|
Jonathan C Roberts EVP & Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
175,811
+49.91%
|
-
|
|
Jan 19
2021
|
Larry J Merlo Director |
SELL
Open market or private sale
|
Direct |
62,893
-10.73%
|
$4,842,761
$77.0 P/Share
|
|
Jan 19
2021
|
Larry J Merlo Director |
BUY
Exercise of conversion of derivative security
|
Direct |
64,350
+9.89%
|
$4,761,900
$74.29 P/Share
|
|
Jan 12
2021
|
Lisa Bisaccia Former EVP & Chief HR Officer |
SELL
Open market or private sale
|
Direct |
25,177
-35.08%
|
$1,938,629
$77.0 P/Share
|
|
Jan 12
2021
|
Lisa Bisaccia Former EVP & Chief HR Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
25,177
+25.97%
|
$1,863,098
$74.29 P/Share
|
|
Jan 08
2021
|
Troyen A Brennan EVP and Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
54,550
+35.17%
|
$4,036,700
$74.29 P/Share
|
|
Jan 08
2021
|
Troyen A Brennan EVP and Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
58,896
-56.14%
|
$4,417,200
$75.0 P/Share
|
|
Jan 08
2021
|
Alan Lotvin EVP&President-PharmacyServices |
SELL
Open market or private sale
|
Direct |
25,836
-75.54%
|
$1,937,700
$75.0 P/Share
|
|
Jan 08
2021
|
Alan Lotvin EVP&President-PharmacyServices |
BUY
Exercise of conversion of derivative security
|
Direct |
25,836
+33.43%
|
$1,653,504
$64.24 P/Share
|